ALK-Abelló A/S - Asset Resilience Ratio
ALK-Abelló A/S (ALK-B) has an Asset Resilience Ratio of 0.98% as of September 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Check how strategically is ALK-Abelló A/S's equity deployed to assess the company's strategic physical and investment asset allocation.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2007–2019)
This chart shows how ALK-Abelló A/S's Asset Resilience Ratio has changed over time. See net asset quality index of ALK-Abelló A/S to measure how much of total assets are equity-financed.
Liquid Assets Composition Over Time
This chart breaks down ALK-Abelló A/S's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see ALK-Abelló A/S market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Dkr0.00 | 0% |
| Short-term Investments | Dkr50.00 Million | 0.98% |
| Total Liquid Assets | Dkr50.00 Million | 0.98% |
Asset Resilience Insights
- Limited Liquidity: ALK-Abelló A/S maintains only 0.98% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
ALK-Abelló A/S Industry Peers by Asset Resilience Ratio
Compare ALK-Abelló A/S's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Argen-X
F:1AE |
Biotechnology | 10.93% |
|
CSL Ltd
AU:CSL |
Biotechnology | 0.41% |
|
Tango Therapeutics Inc
NASDAQ:TNGX |
Biotechnology | 57.90% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 0.72% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
MBX Biosciences, Inc. Common Stock
NASDAQ:MBX |
Biotechnology | 87.20% |
|
Tourmaline Bio Inc.
NASDAQ:TRML |
Biotechnology | 77.17% |
|
PharmaResources (Shanghai) Co. Ltd. A
SHE:301230 |
Biotechnology | 16.35% |
Annual Asset Resilience Ratio for ALK-Abelló A/S (2007–2019)
The table below shows the annual Asset Resilience Ratio data for ALK-Abelló A/S.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-12-31 | -2.91% | Dkr-160.00 Million ≈ $-25.03 Million |
Dkr5.50 Billion ≈ $859.73 Million |
-4.97pp |
| 2018-12-31 | 2.06% | Dkr100.00 Million ≈ $15.65 Million |
Dkr4.87 Billion ≈ $761.16 Million |
-9.02pp |
| 2017-12-31 | 11.07% | Dkr549.00 Million ≈ $85.90 Million |
Dkr4.96 Billion ≈ $775.72 Million |
-0.35pp |
| 2016-12-31 | 11.42% | Dkr548.00 Million ≈ $85.74 Million |
Dkr4.80 Billion ≈ $750.84 Million |
+1.26pp |
| 2015-12-31 | 10.16% | Dkr432.00 Million ≈ $67.59 Million |
Dkr4.25 Billion ≈ $665.26 Million |
+4.08pp |
| 2014-12-31 | 6.08% | Dkr208.00 Million ≈ $32.54 Million |
Dkr3.42 Billion ≈ $534.93 Million |
-9.09pp |
| 2007-12-31 | 15.17% | Dkr428.00 Million ≈ $66.96 Million |
Dkr2.82 Billion ≈ $441.37 Million |
-- |
About ALK-Abelló A/S
ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for th… Read more